Carsten Nieder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carsten Nieder has a total of 322 co-authors. Here are the top co-authors by number of shared publications:
Astrid Dalhaug
Department of Clinical Medicine, Faculty of Health Sciences, UiT-The Arctic University of Norway, 9037, Tromsø, Norway
51 shared publicationsAnca L. Grosu
Department of Radiation Oncology, Medical Center, Medical Faculty, University Freiburg, Freiburg, Germany
34 shared publicationsBård Mannsåker
Department of Oncology and Palliative Medicine, Nordland Hospital, Norway, 8092, Bodø, Norway
33 shared publications- Ellinor Haukland
Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
31 shared publications Adam Pawinski
Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
29 shared publicationsMichael Molls
Department of Radiation Oncology, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany
22 shared publications
Latest Publications
- Open Access
- 25 June 2026
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 202 (9) , 944-953
Individualized radiotherapy of bone metastases from prostate cancer: time trends and 5-year survival results
This article describes a regional study performed in patients with bone metastases from prostate cancer hypothesizing that intensified radiotherapy (metastases directed and prostate directed) may result in longer overall survival. A retrospective study of 246 consecutive male patients who received 347 courses of radiotherapy in the time period 2011-2025 was performed. Patients were stratified into three cohorts spanning 5‑year intervals (2011-2015, 2016-2020, 2021-2025). Survival was analyzed in allcomers and separately in patients without visceral metastases treated within the first year after diagnosis (n = 119). Median overall survival was shortest in the earliest phase of the study (2011-15). The two recent cohorts had similar survival. Outpatients with high performance status irradiated early after diagnosis and to all known sites of disease experienced superior survival. In the subgroup of 119 patients, simultaneous prostate radiotherapy prolonged survival (numerically better than no prostate RT, median 40 vs. 26 months, 5‑year rate 47 vs. 18%, p = 0.11). The impact of bone radiotherapy dose (dichotomized < 3 Gy × 13 or its biological equivalent vs. higher doses) was significant (if synchronous metastases, 5‑year rate 64 vs. 17%, p = 0.026; if metachronous metastases, 5‑year rate 48 vs. 8%, p < 0.001). Bone dose remained significant in multivariate analyses, together with clinical baseline parameters. In our healthcare region, outcomes largely resemble those of prospective trials. Comprehensive radiotherapy to the prostate and bone oligometastases plus guideline-based systemic therapy resulted in favorable 5‑year survival.
- 25 June 2026
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 202 (9) , 944-953
Open AccessIndividualized radiotherapy of bone metastases from prostate cancer: time trends and 5-year survival results
This article describes a regional study performed in patients with bone metastases from prostate cancer hypothesizing that intensified radiotherapy (metastases directed and prostate directed) may result in longer overall survival. A retrospective study of 246 consecutive male patients who received 347 courses of radiotherapy in the time period 2011-2025 was performed. Patients were stratified into three cohorts spanning 5‑year intervals (2011-2015, 2016-2020, 2021-2025). Survival was analyzed in allcomers and separately in patients without visceral metastases treated within the first year after diagnosis (n = 119). Median overall survival was shortest in the earliest phase of the study (2011-15). The two recent cohorts had similar survival. Outpatients with high performance status irradiated early after diagnosis and to all known sites of disease experienced superior survival. In the subgroup of 119 patients, simultaneous prostate radiotherapy prolonged survival (numerically better than no prostate RT, median 40 vs. 26 months, 5‑year rate 47 vs. 18%, p = 0.11). The impact of bone radiotherapy dose (dichotomized < 3 Gy × 13 or its biological equivalent vs. higher doses) was significant (if synchronous metastases, 5‑year rate 64 vs. 17%, p = 0.026; if metachronous metastases, 5‑year rate 48 vs. 8%, p < 0.001). Bone dose remained significant in multivariate analyses, together with clinical baseline parameters. In our healthcare region, outcomes largely resemble those of prospective trials. Comprehensive radiotherapy to the prostate and bone oligometastases plus guideline-based systemic therapy resulted in favorable 5‑year survival.
- Open Access
- 22 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 221, 111611
Radiotherapy at the limits of age: evolving fractionation strategies, symptom palliation, and survival in nonagenarians
- 22 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 221, 111611
Open AccessRadiotherapy at the limits of age: evolving fractionation strategies, symptom palliation, and survival in nonagenarians
- 27 March 2026
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 46 (4) , 2045-2051
Survival Then and Now in Patients With Surgically Resected Brain Metastasis: Major Improvement in Cases With Controlled Primary Tumor
The aim of this study was to analyze the survival outcomes in different time periods (recent, 2016-2024; earlier, 2007-2015; historical, before 2007) for patients with brain metastasis managed with surgical resection and postoperative radiotherapy. Major changes in systemic therapy over time were hypothesized to translate into better survival. A retrospective analysis was performed that included 174 patients, largely with single brain metastasis and Karnofsky performance status (KPS) 80-100. Uni- and multivariate analyses of actuarial overall survival were performed. Three significant prognostic factors for survival emerged: KPS, primary tumor control, and administration of systemic therapy after treatment of brain metastasis. In all patients, and also those who received systemic therapy after treatment for brain metastasis, survival remained similar (median of 16 months) for all three time periods (recent, earlier, historical). In patients with controlled primary tumor, survival increased from 17.5 (historical) to 35.8 months, p=0.01. Patients with resected and postoperatively irradiated brain metastasis benefited from additional systemic therapy. Only one subgroup experienced major survival prolongation in more recent years: those with controlled primary tumor. Therefore, efforts to optimize primary tumor control, such as surgery and radical radiotherapy, may play an important role in multimodal treatment paradigms.
- 27 March 2026
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 46 (4) , 2045-2051
Survival Then and Now in Patients With Surgically Resected Brain Metastasis: Major Improvement in Cases With Controlled Primary Tumor
The aim of this study was to analyze the survival outcomes in different time periods (recent, 2016-2024; earlier, 2007-2015; historical, before 2007) for patients with brain metastasis managed with surgical resection and postoperative radiotherapy. Major changes in systemic therapy over time were hypothesized to translate into better survival. A retrospective analysis was performed that included 174 patients, largely with single brain metastasis and Karnofsky performance status (KPS) 80-100. Uni- and multivariate analyses of actuarial overall survival were performed. Three significant prognostic factors for survival emerged: KPS, primary tumor control, and administration of systemic therapy after treatment of brain metastasis. In all patients, and also those who received systemic therapy after treatment for brain metastasis, survival remained similar (median of 16 months) for all three time periods (recent, earlier, historical). In patients with controlled primary tumor, survival increased from 17.5 (historical) to 35.8 months, p=0.01. Patients with resected and postoperatively irradiated brain metastasis benefited from additional systemic therapy. Only one subgroup experienced major survival prolongation in more recent years: those with controlled primary tumor. Therefore, efforts to optimize primary tumor control, such as surgery and radical radiotherapy, may play an important role in multimodal treatment paradigms.
- Open Access
- 1 March 2026
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 6 (2) , 227-235
Patient-reported Symptoms Differ Between Patients With Brain Metastasis Starting Either Focal Stereotactic Radiotherapy or Whole-brain Radiotherapy
Background/Aim: The presence of brain metastasis is often associated with clinical symptoms and reduced quality-of life scores, potentially triggering palliative care needs. Previous studies have employed the Edmonton symptom assessment system (ESAS) to this end. However, contemporary patient-reported ESAS data from cohorts managed with different radiotherapy techniques rather than whole-brain radiotherapy (WBRT) alone are scarce. Therefore, the aim of this study was to compare ESAS symptom severity before WBRT to that before stereotactic radiosurgery or fractionated radiotherapy (SRS/FSRT). Materials and Methods: This was a retrospective analysis (2013-2024, n=102) of patients with brain metastasis assessed with ESAS in routine clinical practice in Norway. Patients were stratified based on radiotherapy approach (WBRT±boost versus SRS/FSRT). ESAS scores of 0 correspond to absence of symptoms (maximum intensity: 10). Results: For the whole study group, fatigue and overall wellbeing scores were highest (mean 3.9 and 3.4, respectively). The lowest scores were those for nausea and constipation (mean 1.2 and 1.4, respectively). Within the WBRT cohort, no significant differences were observed between ESAS scores of boost versus no boost patients. When comparing WBRT to SRS/FSRT, we found that WBRT patients reported significantly higher anxiety scores (mean 2.6 vs. 1.1, p=0.03). Similar trends emerged for fatigue (mean 4.1 vs. 2.7, p=0.056, i.e., not significant) and overall wellbeing (mean 3.7 vs. 2.5, p=0.087). The sum of symptom scores was significantly higher in the WBRT cohort (mean 31.7), compared to the SRS/FSRT cohort (mean 18.5), p=0.03. Conclusion: When employing ESAS screening to provide additional palliative care services to patients with brain metastasis who start radiotherapy, clinicians should be aware of the fact that patients undergoing WBRT may have worse symptom burden and higher needs than patients undergoing SRS/FSRT. This is particularly evident for anxiety, fatigue and overall wellbeing, and not explained by differences in number of brain metastasis and diagnostic setting (regular imaging surveillance versus clinical trigger).
- 1 March 2026
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 6 (2) , 227-235
Open AccessPatient-reported Symptoms Differ Between Patients With Brain Metastasis Starting Either Focal Stereotactic Radiotherapy or Whole-brain Radiotherapy
Background/Aim: The presence of brain metastasis is often associated with clinical symptoms and reduced quality-of life scores, potentially triggering palliative care needs. Previous studies have employed the Edmonton symptom assessment system (ESAS) to this end. However, contemporary patient-reported ESAS data from cohorts managed with different radiotherapy techniques rather than whole-brain radiotherapy (WBRT) alone are scarce. Therefore, the aim of this study was to compare ESAS symptom severity before WBRT to that before stereotactic radiosurgery or fractionated radiotherapy (SRS/FSRT). Materials and Methods: This was a retrospective analysis (2013-2024, n=102) of patients with brain metastasis assessed with ESAS in routine clinical practice in Norway. Patients were stratified based on radiotherapy approach (WBRT±boost versus SRS/FSRT). ESAS scores of 0 correspond to absence of symptoms (maximum intensity: 10). Results: For the whole study group, fatigue and overall wellbeing scores were highest (mean 3.9 and 3.4, respectively). The lowest scores were those for nausea and constipation (mean 1.2 and 1.4, respectively). Within the WBRT cohort, no significant differences were observed between ESAS scores of boost versus no boost patients. When comparing WBRT to SRS/FSRT, we found that WBRT patients reported significantly higher anxiety scores (mean 2.6 vs. 1.1, p=0.03). Similar trends emerged for fatigue (mean 4.1 vs. 2.7, p=0.056, i.e., not significant) and overall wellbeing (mean 3.7 vs. 2.5, p=0.087). The sum of symptom scores was significantly higher in the WBRT cohort (mean 31.7), compared to the SRS/FSRT cohort (mean 18.5), p=0.03. Conclusion: When employing ESAS screening to provide additional palliative care services to patients with brain metastasis who start radiotherapy, clinicians should be aware of the fact that patients undergoing WBRT may have worse symptom burden and higher needs than patients undergoing SRS/FSRT. This is particularly evident for anxiety, fatigue and overall wellbeing, and not explained by differences in number of brain metastasis and diagnostic setting (regular imaging surveillance versus clinical trigger).
- Open Access
- 1 January 2026
- Published by Termedia Sp. z.o.o. in Contemporary Oncology
- Vol. 30 (1) , 40-46
Best supportive care in patients with brain metastases: impact of the primary tumour type on survival
Introduction The study was aimed to analyse the impact of the tumour type and other patient- and disease-related baseline parameters in a consecutive cohort managed with best supportive care (BSC) in northern Norway. Material and methods This is a retrospective analysis of 149 patients...
- 1 January 2026
- Published by Termedia Sp. z.o.o. in Contemporary Oncology
- Vol. 30 (1) , 40-46
Open AccessBest supportive care in patients with brain metastases: impact of the primary tumour type on survival
Introduction The study was aimed to analyse the impact of the tumour type and other patient- and disease-related baseline parameters in a consecutive cohort managed with best supportive care (BSC) in northern Norway. Material and methods This is a retrospective analysis of 149 patients...
- Open Access
- 2 November 2025
- Published by Taylor & Francis in Immunotherapy
- Vol. 17 (16) , 1177-1187
Consequences of adverse events in cancer immunotherapy combinations – a comprehensive real-world analysis
Immune checkpoint inhibitors (ICIs) are pivotal in systemic anticancer therapy. The aim of the study was to investigate incidence, severity and consequences of immune-related adverse events (irAEs) in ICI combinations by comparing different adverse events classification systems. A retrospective multicentre cohort study included patients treated with ICI combinations. IrAEs were assessed by CTCAE v.5, NCC MERP index and SITC consensus for chronic irAEs. Among 612 patients, 244 (40%) experienced 354 irAEs, in total 58 irAEs per 100 patients varying between treatments. Higher incidence was observed for autoimmune disease, thoracic radiotherapy, melanoma, dual ICI and ICI/TKI. Severe irAEs occurred in 147 patients, leading to treatment discontinuation and hospitalization in half of the patients. Chronic irAEs were common, with 64% persisting beyond three months after ICI discontinuation, 22% of these resolved (median 135 steroid days, 154 days to resolution). Common chronic toxicities included endocrine, pulmonary or rheumatic irAEs. Fatal irAEs affected 16 patients, primarily from pneumonitis, colitis or hepatitis. NCC MERP better captured clinical consequences compared to CTCAE, while SITC criteria uniquely identified long-term irAEs. Severe and chronic irAEs were frequent, emphasizing the need for improved communication about irAE management and prospective studies with revised toxicity definitions.ClinicalTrials.govIDNCT06476158.
- 2 November 2025
- Published by Taylor & Francis in Immunotherapy
- Vol. 17 (16) , 1177-1187
Open AccessConsequences of adverse events in cancer immunotherapy combinations – a comprehensive real-world analysis
Immune checkpoint inhibitors (ICIs) are pivotal in systemic anticancer therapy. The aim of the study was to investigate incidence, severity and consequences of immune-related adverse events (irAEs) in ICI combinations by comparing different adverse events classification systems. A retrospective multicentre cohort study included patients treated with ICI combinations. IrAEs were assessed by CTCAE v.5, NCC MERP index and SITC consensus for chronic irAEs. Among 612 patients, 244 (40%) experienced 354 irAEs, in total 58 irAEs per 100 patients varying between treatments. Higher incidence was observed for autoimmune disease, thoracic radiotherapy, melanoma, dual ICI and ICI/TKI. Severe irAEs occurred in 147 patients, leading to treatment discontinuation and hospitalization in half of the patients. Chronic irAEs were common, with 64% persisting beyond three months after ICI discontinuation, 22% of these resolved (median 135 steroid days, 154 days to resolution). Common chronic toxicities included endocrine, pulmonary or rheumatic irAEs. Fatal irAEs affected 16 patients, primarily from pneumonitis, colitis or hepatitis. NCC MERP better captured clinical consequences compared to CTCAE, while SITC criteria uniquely identified long-term irAEs. Severe and chronic irAEs were frequent, emphasizing the need for improved communication about irAE management and prospective studies with revised toxicity definitions.ClinicalTrials.govIDNCT06476158.
- 4 March 2025
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 45 (3) , 1149-1158
Radiotherapy for Bone Metastases in Patients With Excellent Performance Status: Patterns of Care and Prognostic Factors for Survival
Background/Aim: The aim was to analyze patterns of care, e.g., fractionation of radiotherapy and treatment completion, and prognostic factors for survival in patients irradiated for bone metastases who had excellent Eastern Cooperative Oncology Group (ECOG) performance status (PS), defined as ECOG PS 0. Patients and Methods: A retrospective analysis was performed (2010-2024, n=1,244 radiotherapy courses) that included patients with bone metastases treated with conventional palliative or stereotactic single- or multi-fraction regimens (SBRT). Results: Patients with ECOG PS 0 (n=129, 10%) had 0% 30-day mortality, 99% 3-months survival, and 83% 12-months survival. Only three of 129 (2%) did not complete radiotherapy. Most patients had prostate or breast cancer with bone-only metastases. In restricted analysis without inclusion of blood test results, five significant predictors of unfavorable survival emerged: steroid medication, no continuation of systemic therapy, progressive disease outside of the irradiated target volume(s), adrenal gland metastasis, and prescription of fewer radiotherapy fractions. With blood tests included, the final multivariate model suggested that survival varied with lactate dehydrogenase (strata: normal/elevated), adrenal gland metastases (yes/no), progressive disease outside of the irradiated target volume(s) (yes/no), and fraction number (>10/≤10). Conclusion: Many patients with ECOG PS 0 experience long-term survival, influenced by disease behavior and choice of fractionation, among others. The impact of fractionation was due to imbalances in baseline characteristics, e.g., proportion of patients with de novo hormone-sensitive prostate cancer with low-volume disease receiving fractionated radiotherapy to both prostate and bone metastases. No clear impact of equivalent radiation dose in 2-Gy fractions on survival emerged.
- 4 March 2025
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 45 (3) , 1149-1158
Radiotherapy for Bone Metastases in Patients With Excellent Performance Status: Patterns of Care and Prognostic Factors for Survival
Background/Aim: The aim was to analyze patterns of care, e.g., fractionation of radiotherapy and treatment completion, and prognostic factors for survival in patients irradiated for bone metastases who had excellent Eastern Cooperative Oncology Group (ECOG) performance status (PS), defined as ECOG PS 0. Patients and Methods: A retrospective analysis was performed (2010-2024, n=1,244 radiotherapy courses) that included patients with bone metastases treated with conventional palliative or stereotactic single- or multi-fraction regimens (SBRT). Results: Patients with ECOG PS 0 (n=129, 10%) had 0% 30-day mortality, 99% 3-months survival, and 83% 12-months survival. Only three of 129 (2%) did not complete radiotherapy. Most patients had prostate or breast cancer with bone-only metastases. In restricted analysis without inclusion of blood test results, five significant predictors of unfavorable survival emerged: steroid medication, no continuation of systemic therapy, progressive disease outside of the irradiated target volume(s), adrenal gland metastasis, and prescription of fewer radiotherapy fractions. With blood tests included, the final multivariate model suggested that survival varied with lactate dehydrogenase (strata: normal/elevated), adrenal gland metastases (yes/no), progressive disease outside of the irradiated target volume(s) (yes/no), and fraction number (>10/≤10). Conclusion: Many patients with ECOG PS 0 experience long-term survival, influenced by disease behavior and choice of fractionation, among others. The impact of fractionation was due to imbalances in baseline characteristics, e.g., proportion of patients with de novo hormone-sensitive prostate cancer with low-volume disease receiving fractionated radiotherapy to both prostate and bone metastases. No clear impact of equivalent radiation dose in 2-Gy fractions on survival emerged.
- Open Access
- 1 March 2025
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 5 (2) , 138-145
Impact of Body Mass Index on Survival After Docetaxel Chemotherapy for Metastatic Castration‐resistant Prostate Cancer
Background/Aim: Several recent studies, varying in design and the number of baseline parameters analyzed, suggest that a lower body mass index (BMI) is associated with shorter survival in men beginning treatment for metastatic castration-resistant prostate cancer (MCRPC), including treatments such as docetaxel. This study aimed to analyze the impact of BMI and numerous covariates on survival in a homogeneously treated cohort of Caucasian men who received first-line docetaxel for MCRPC. Patients and Methods: This retrospective analysis included 112 consecutive patients managed between 2009 and 2023. Comorbidity, medications, and blood tests were included. Both, uni- and multivariate tests were performed. Results: The median age of the patients was 70 years with a median BMI of 26.8 kg/m2. Most patients were free from serious comorbidities, had bone-only metastases, and experienced metachronous development of metastases. Hemoglobin values were significantly lower in patients with lower BMI (median 11.9 versus 13.0 g/dl, p=0.001). Lean patients had numerically shorter survival compared to overweight/obese patients (median 11.8 versus 19.4 months, p=0.15). In multivariate analysis of prognostic factors, only three baseline parameters retained statistical significance: serum lactate dehydrogenase (p=0.03), hemoglobin (p=0.007), and the presence of non-bone metastases (p=0.004). Conclusion: An interaction between BMI and hemoglobin was present in metastatic castration-resistant prostate cancer patients after docetaxel chemotherapy, explaining the observed survival difference between lean and overweight/obese patients. Comorbidities and medications had no significant impact on survival in this population with limited prognosis (median survival 16.1 months).
- 1 March 2025
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 5 (2) , 138-145
Open AccessImpact of Body Mass Index on Survival After Docetaxel Chemotherapy for Metastatic Castration‐resistant Prostate Cancer
Background/Aim: Several recent studies, varying in design and the number of baseline parameters analyzed, suggest that a lower body mass index (BMI) is associated with shorter survival in men beginning treatment for metastatic castration-resistant prostate cancer (MCRPC), including treatments such as docetaxel. This study aimed to analyze the impact of BMI and numerous covariates on survival in a homogeneously treated cohort of Caucasian men who received first-line docetaxel for MCRPC. Patients and Methods: This retrospective analysis included 112 consecutive patients managed between 2009 and 2023. Comorbidity, medications, and blood tests were included. Both, uni- and multivariate tests were performed. Results: The median age of the patients was 70 years with a median BMI of 26.8 kg/m2. Most patients were free from serious comorbidities, had bone-only metastases, and experienced metachronous development of metastases. Hemoglobin values were significantly lower in patients with lower BMI (median 11.9 versus 13.0 g/dl, p=0.001). Lean patients had numerically shorter survival compared to overweight/obese patients (median 11.8 versus 19.4 months, p=0.15). In multivariate analysis of prognostic factors, only three baseline parameters retained statistical significance: serum lactate dehydrogenase (p=0.03), hemoglobin (p=0.007), and the presence of non-bone metastases (p=0.004). Conclusion: An interaction between BMI and hemoglobin was present in metastatic castration-resistant prostate cancer patients after docetaxel chemotherapy, explaining the observed survival difference between lean and overweight/obese patients. Comorbidities and medications had no significant impact on survival in this population with limited prognosis (median survival 16.1 months).
- Open Access
- 1 March 2025
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 5 (2) , 171-178
External Validation of an Extended Prognostic Assessment Model in Patients With Brain Metastases from Small‐cell Lung Cancer
Background/Aim: Recently, the small-cell lung cancer (SCLC) grade model for patients with brain metastases was developed by a Japanese group. It includes sex, performance status, number of brain metastases, primary tumor control and presence of extracranial metastases. The aim of the present study was to validate this prognostic score in a European cohort of patients. Patients and Methods: The retrospective validation study included 189 patients from two centers in Germany and Norway. Survival according to the SCLC grade score was evaluated. Additional prognostic factors were analyzed. Results: Median survival was 7.5 months. The 3-tiered SCLC grade score based on the sum of adverse prognostic features was significantly associated with survival (p<0.001): A higher point sum resulted in shorter survival. However, in our validation cohort, age affected survival to the same degree as several parameters that were part of the score. Conclusion: This validation study supports the international applicability of the SCLC grade model. Age, which has also been identified as a relevant prognostic factor in other previous studies (including the SCLC Graded Prognostic Assessment), may deserve consideration when trying to optimize survival prediction. Given that different studies identified different age limits, e.g., 70 or 75 years, merged databases are needed to provide definitive conclusions.
- 1 March 2025
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 5 (2) , 171-178
Open AccessExternal Validation of an Extended Prognostic Assessment Model in Patients With Brain Metastases from Small‐cell Lung Cancer
Background/Aim: Recently, the small-cell lung cancer (SCLC) grade model for patients with brain metastases was developed by a Japanese group. It includes sex, performance status, number of brain metastases, primary tumor control and presence of extracranial metastases. The aim of the present study was to validate this prognostic score in a European cohort of patients. Patients and Methods: The retrospective validation study included 189 patients from two centers in Germany and Norway. Survival according to the SCLC grade score was evaluated. Additional prognostic factors were analyzed. Results: Median survival was 7.5 months. The 3-tiered SCLC grade score based on the sum of adverse prognostic features was significantly associated with survival (p<0.001): A higher point sum resulted in shorter survival. However, in our validation cohort, age affected survival to the same degree as several parameters that were part of the score. Conclusion: This validation study supports the international applicability of the SCLC grade model. Age, which has also been identified as a relevant prognostic factor in other previous studies (including the SCLC Graded Prognostic Assessment), may deserve consideration when trying to optimize survival prediction. Given that different studies identified different age limits, e.g., 70 or 75 years, merged databases are needed to provide definitive conclusions.
- Open Access
- 10 November 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 202, 110624
Ongoing prospective studies on reirradiation: A systematic review of a clinical trials database
- 10 November 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 202, 110624
Open AccessOngoing prospective studies on reirradiation: A systematic review of a clinical trials database